Herramienta computacional para la documentación de pruebas de software enmarcado en actividades de investigación

El presente artículo describe el diseño de una herramienta computacional para la documentación de pruebas de software. La herramienta permite gestionar documentos como el plan maestro de pruebas; los planes de nivel, casos  y procedimientos de prueba; reporte de anomalías y reporte de pruebas, que hacen parte de una adecuada documentación de pruebas de software. Utilizando diagrama de paquetes  y casos de uso se muestra la funcionalidad disponible en la herramienta, la cual ha sido diseñada a partir de la norma IEEE 829

Perspectivas literarias: traducción e intertextualidad

En este libro hemos reunido un conjunto de trabajos que exploran temas relacionados con la traducción literaria y con los estudios literarios desde una perspectiva múltiple y comparada, pues creemos que, en estos tiempos, es valioso detenerse a analizar experiencias complejas con respecto a las prácticas literarias que permiten la comunicación intercultural, ya que ésta es una vía para cuestionar visiones nacionalistas que, en ocasiones, tienden a achatar el panorama en lugar de reconocer la hibridez y la heterogeneidad de los discursos literarios. Se trata de analizar estos temas desde distintos ángulos, tales como la traducción, las intertextualidades temáticas, la formación de traductores, la perspectiva de los lectores, la construcción del canon por distintas instancias culturales y los estudios comparados

The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus

OBJECTIVE: To identify the prevalence and factors associated with cervical human papillomavirus infection in women with systemic lupus erythematosus METHODS: This cross-sectional study collected traditional and systemic lupus erythematosus-related disease risk factors, including conventional and biologic therapies. A gynecological evaluation and cervical cytology screen were performed. Human papillomavirus detection and genotyping were undertaken by PCR and linear array assay. RESULTS: A total of 148 patients were included, with a mean age and disease duration of 42.5±11.8 years and 9.7±5.3 years, respectively. The prevalence of squamous intraepithelial lesions was 6.8%. The prevalence of human papillomavirus infection was 29%, with human papillomavirus subtype 59 being the most frequent. Patients with human papillomavirus were younger than those without the infection (38.2±11.2 vs. 44.2±11.5 years, respectively; p = 0.05), and patients with the virus had higher daily prednisone doses (12.8±6.8 vs. 9.7±6.7 mg, respectively; p = 0.01) and cumulative glucocorticoid doses (14.2±9.8 vs. 9.7±7.3 g, respectively; p = 0.005) compared with patients without. Patients with human papillomavirus infection more frequently received rituximab than those without (20.9% vs. 8.5%, respectively; p = 0.03). In the multivariate analysis, only the cumulative glucocorticoid dose was associated with human papillomavirus infection. CONCLUSIONS: The cumulative glucocorticoid dose may increase the risk of human papillomavirus infection. Although rituximab administration was more frequent in patients with human papillomavirus infection, no association was found. Screening for human papillomavirus infection is recommended in women with systemic lupus erythematosus

PLANEACIÓN DIDÁCTICA GENERAL DE LA ASIGNATURA: ARITMÉTICA Y LENGUAJE MATEMÁTICO 2017B

GUÍA DIDÁCTICA / PLANEACIÓN DIDÁCTICA (NMS

Desarrollo de un dispositivo multicanal para la resección avanzada de tumores rectales mediante endoscopia flexible y cirugía endoscópica transanal UNI-VEC®

[ES] El Instituto de Biomecánica (IBV) ha desarrollado, junto con el Servicio Gallego de Salud (Sergas) y la empresa VECMEDICAL SPAIN S.L., un innovador dispositivo multicanal para la realización de endoscopia flexible o rígida intrarrectal y extirpación asistida por instrumentos rígidos de lesiones rectales no susceptibles de ser tratadas mediante las técnicas convencionales de endoscopia flexible. Se partió de una idea conceptual definida por el grupo clínico, liderado por el Dr. José Noguera, y se llevaron a cabo conjuntamente todas las etapas de desarrollo. Desde el diseño conceptual, análisis de riesgos, pruebas in vitro de funcionalidad, rediseño, experimentación animal, diseño para fabricación, hasta finalizar con la generación de la documentación necesaria para el marcado CE y estudio clínico en humanos.Al Sergas por promover y financiar la investigación. El plan de innovación sanitaria Código 100 se ejecuta en el marco de un convenio de colaboración entre el Sergas y el Ministerio de Economía, lndustria y Competitividad (MEIC), financiado en un 80% por Fondos FEDER 2014-2020 del Programa Operativo de Crecimiento lnteligente (POCINT).Noguera Aguilar, JF.; Gómez Herrero, JA.; Navarro Garcia, FJ.; Peris Serra, JL.; Atienza Vicente, CM.; Solera Navarro, MJ. (2021). Desarrollo de un dispositivo multicanal para la resección avanzada de tumores rectales mediante endoscopia flexible y cirugía endoscópica transanal UNI-VEC®. Revista de Biomecánica (Online). (68):1-5. http://hdl.handle.net/10251/187381156

PLANEACIÓN DIDÁCTICA GENERAL DE LA ASIGNATURA: TRIGONOMETRÍA 2017- B

GUÍA DIDÁCTICA / PLANEACIÓN DIDÁCTICA (NMS

Guía docente común de las titulaciones de Ingeniero en Electrónica en las universidades andaluzas

El presente documento constituye el resultado del trabajo elaborado de acuerdo con la Convocatoria de Elaboración de Guías Docentes de Titulaciones Andaluzas conforme al Sistema de Créditos Europeos (años 2005/2006) de la Dirección General de Universidades, dependiente de la Secretaría General de Universidades, Investigación y Tecnología de la Consejería de Innovación, Ciencia y Empresa de la Junta de Andalucía

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy : a position paper

Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CAR-T constructs are in research for both hematological and non-hematological diseases. Most of the patients receiving CAR-T therapy will develop fever at some point after infusion, mainly due to cytokine release syndrome (CRS). The onset of CRS is often indistinguishable from an infection, which makes management of these patients challenging. In addition to the lymphodepleting chemotherapy and CAR T cells, the treatment of complications with corticosteroids and/or tocilizumab increases the risk of infection in these patients. Data regarding incidence, risk factors and prevention of infections in patients receiving CAR-T cell therapy are scarce. To assist in patient care, a multidisciplinary team from hospitals designated by the Spanish Ministry of Health to perform CAR-T therapy prepared these recommendations. We reviewed the literature on the incidence, risk factors, and management of infections in adult and pediatric patients receiving CAR-T cell treatment. Recommendations cover different areas: monitoring and treatment of hypogammaglobulinemia, prevention, prophylaxis, and management of bacterial, viral, and fungal infections as well as vaccination prior and after CAR-T cell therapy

A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy

Biomarkers; Colorectal cancer; ImmunotherapyBiomarcadors; Càncer colorectal; ImmunoteràpiaBiomarcadores; Cáncer colorrectal; InmunoterapiaThe search for immunotherapy biomarkers in Microsatellite Instability High/Deficient Mismatch Repair system (MSI-H/dMMR) metastatic colorectal cancer (mCRC) is an unmet need. Sixteen patients with mCRC and MSI-H/dMMR (determined by either immunohistochemistry or polymerase chain reaction) treated with PD-1/PD-L1 inhibitors at our institution were included. According to whether the progression-free survival with PD-1/PD-L1 inhibitors was longer than 6 months or shorter, patients were clustered into the IT-responder group (n: 9 patients) or IT-resistant group (n: 7 patients), respectively. In order to evaluate determinants of benefit with PD-1/PD-L1 inhibitors, we performed multimodal analysis including genomics (through NGS panel tumour-only with 431 genes) and the immune microenvironment (using CD3, CD8, FOXP3 and PD-L1 antibodies). The following mutations were more frequent in IT-resistant compared with IT-responder groups: B2M (4/7 versus 2/9), CTNNB1 (2/7 versus 0/9), and biallelic PTEN (3/7 versus 1/9). Biallelic ARID1A mutations were found exclusively in the IT-responder group (4/9 patients). Tumour mutational burden did not correlate with immunotherapy benefit, neither the rate of indels in homopolymeric regions. Of note, biallelic ARID1A mutated tumours had the highest immune infiltration and PD-L1 scores, contrary to tumours with CTNNB1 mutation. Immune microenvironment analysis showed higher densities of different T cell subpopulations and PD-L1 expression in IT-responders. Misdiagnosis of MSI-H/dMMR inferred by discordances between immunohistochemistry and polymerase chain reaction was only found in the IT-resistant population (3/7 patients). Biallelic ARID1A mutations and Wnt signalling activation through CTNNB1 mutation were associated with high and low T cell immune infiltrates, respectively, and deserve special attention as determinants of response to PD-1/PD-L1 inhibitors. The non-MSI-H phenotype in dMMR is associated with poor benefit to immunotherapy. Our results suggest that mechanisms of resistance to immunotherapy are multi-factorial.This research was funded by Merck Research Grants (Call 2018) in the Area of Colorectal Cancer Clinical Investigation